{"nctId":"NCT04136366","briefTitle":"The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy","startDateStruct":{"date":"2019-11-15","type":"ACTUAL"},"conditions":["Proliferative Vitreoretinopathy"],"count":106,"armGroups":[{"label":"ADX-2191 (intravitreal methotrexate 0.8%)","type":"EXPERIMENTAL","interventionNames":["Drug: ADX-2191 (intravitreal methotrexate 0.8%)"]},{"label":"Standard surgical care procedure","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Standard surgical care procedure"]}],"interventions":[{"name":"ADX-2191 (intravitreal methotrexate 0.8%)","otherNames":[]},{"name":"Standard surgical care procedure","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject is 18 years or older of any gender or race\n2. Subject is undergoing pars plana vitrectomy due to recurrent retinal detachment due to proliferative vitreoretinopathy or open globe injury\n3. Subject is willing and able to provide written informed consent, comply with clinical trial procedures, and return for all clinical trial visits\n4. Subjects of childbearing potential must agree to use two forms of birth control for the duration of the clinical trial\n\nExclusion Criteria:\n\n1. History of severe non-proliferative or proliferative diabetic retinopathy\n2. Other planned eye surgery during the course of the trial\n3. Participation in a clinical trial with an investigational medicinal product or investigational device within 90 days of subject enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Recurrent Retinal Detachment Compared to Historical Rates","description":"Percentage of subjects with recurrent retinal detachments requiring reoperation compared to historical rates","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"20.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Recurrent Retinal Detachment","description":"Number of subjects with recurrent retinal detachment due to proliferative vitreoretinopathy","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Best-corrected Visual Acuity","description":"Change from baseline of best-corrected visual acuity using an early treatment diabetic retinopathy study (ETDRS) chart. The ETDRS chart contains seventy letters and the visual acuity letter score is equal to the total number of letters read correctly (0 = worst outcome, 70 = best outcome).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":"23.2"},{"groupId":"OG001","value":"22.5","spread":"27.4"}]}]}]},{"type":"SECONDARY","title":"Macular Epiretinal Membrane","description":"Number of subjects with macular epiretinal membrane assessed by spectral domain optical coherence tomography for study eye","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Intraocular Pressure Less Than 5 mmHg for Study Eye","description":"Number of subjects with intraocular pressure less than 5 mmHg for study eye","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Central Macular Subfield Thickness","description":"Number of subjects with central macular subfield thickness assessed by spectral domain optical coherence tomography for study eye","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"384.4","spread":"185.24"},{"groupId":"OG001","value":"473.7","spread":"228.95"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":68},"commonTop":["Eye pain","Punctate keratitis","Cystoid macular oedema","Macular fibrosis","Intraocular pressure increased"]}}}